Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort by In-Kyu Yoon, Anon Srikiatkhachorn, Maria Theresa Alera, Stefan Fernandez, Derek A.T. Cummings, Henrik Salje

Subjects: Get full text

Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy by Andrea Callegaro, Fabian Tibaldi

Subjects: Get full text

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights by Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L

Subjects: Get full text

A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy by Mei Li, Mei Li, Mei Li, Jun Liao, Jun Liao, Jun Liao, Li Wang, Li Wang, Li Wang, Tianye Lv, Tianye Lv, Tianye Lv, Qianfu Sun, Qianfu Sun, Qianfu Sun, Yan Xu, Yan Xu, Yan Xu, Zhi Guo, Zhi Guo, Zhi Guo, Manman Quan, Manman Quan, Manman Quan, Hao Qin, Hao Qin, Hao Qin, Haoyang Yu, Kai Zhang, Kai Zhang, Wenge Xing, Wenge Xing, Wenge Xing, Haipeng Yu, Haipeng Yu, Haipeng Yu

Subjects: Get full text

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis by Yin Yang, Jianyang Wang, Wenqing Wang, Tao Zhang, Jingjing Zhao, Yu Wang, Yexiong Li, Luhua Wang, Nan Bi

Subjects: Get full text

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis by Yin Yang, Jianyang Wang, Wenqing Wang, Tao Zhang, Jingjing Zhao, Yu Wang, Yexiong Li, Luhua Wang, Nan Bi

Subjects: Get full text

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022Research in context by Xingxian Luo, Xin Du, Lin Huang, Qixiang Guo, Xufeng Lv, Cen Wang, Haopeng Liu, Yue Zhou, Xuecai Xue, Zhuangqi Li, Jingwen Liu, Shein-Chung Chow, Yue Yang

Subjects: Get full text

Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis by L. Leung, J.M. Kirkwood, S. Srinivasan, M. Dyer, A. Qian, M.-M. Pourrahmat, E. Kasireddy, J.R. May, A. Moshyk, M. Kurt

Subjects: “…surrogate endpoints…”
Get full text

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs by Oriol Solà-Morales, Timm Volmer, Lorenzo Mantovani

Subjects: Get full text

Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial) by Danni Li, Michelle M. Mielke, W. Robert Bell, Cavan Reilly, Lin Zhang, Feng Vankee Lin, Fang Yu

“…Blood biomarkers represent a clinically applicable alternative surrogate endpoint for RCTs that would be both cost-effective and minimally invasive, but little is known about their value as surrogate endpoints for treatment responses in the prevention of AD dementia. …”
Get full text

Predicting Efficacy of a Purified Inactivated Zika Virus Vaccine in Flavivirus-Naïve Humans Using an Immunological Correlate of Protection in Non-Human Primates by Camilo J. Acosta, Francesco Nordio, David A. Boltz, Whitney R. Baldwin, Greg Hather, Eloi Kpamegan

Subjects: Get full text

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China by Kexin Ling, Huli Qin, Yiman Feng, Hongxi Che, Jinxi Ding, Jinxi Ding, Wei Li, Wei Li

Subjects: Get full text

Incorporating Covariates into Measures of Surrogate Paradox Risk by Fatema Shafie Khorassani, Jeremy M. G. Taylor, Niko Kaciroti, Michael R. Elliott

Subjects: Get full text

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas by Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim

Subjects: Get full text

Effect of estimating equations for glomerular filtration rate on novel surrogate markers for renal outcome by Kipyo Kim, Eunji Baek, Suryeong Go, Hyung-Eun Son, Ji-Young Ryu, Yongjin Yi, Jong Cheol Jeong, Sejoong Kim, Ho Jun Chin

Subjects: Get full text

A Clinical Trial Design for Evaluating Topical Antimicrobials in Chronic Wounds: The BLEU Trial by Thomas Serena, Emily King, Theresa Boyer, Khristina Harrell

Subjects: Get full text

The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China by Mingjun Rui, Mingjun Rui, Zijing Wang, Zijing Wang, Zhengyang Fei, Zhengyang Fei, Yao Wu, Yao Wu, Yingcheng Wang, Yingcheng Wang, Lei Sun, Ye Shang, Ye Shang, Hongchao Li, Hongchao Li

Subjects: Get full text

Selection of Endpoints for Clinical Studies of Ophthalmic Drugs by M. O. Komarova

Subjects: Get full text

Measurable residual disease in chronic lymphocytic leukemia by Giulia Benintende, Federico Pozzo, Idanna Innocenti, Francesco Autore, Alberto Fresa, Giovanni D’Arena, Valter Gattei, Luca Laurenti

Subjects: Get full text

Challenges and opportunities for designing clinical trials for antibody mediated rejection by Suryanarayanan Balakrishnan, Mariam P. Alexander, Carrie Schinstock

Subjects: Get full text